Peking University Biologics

Glofitamab (COLUMVI, internal code ML45833) is a B-lymphocyte antigen CD20-binding agent developed by Peking University Third Hospital for the treatment of mantle cell lymphoma (MCL). The drug is a small-molecule antineoplastic agent currently in Phase 2 clinical development in China, with an active trial (NCT07460362) as of the latest disclosed milestone on 2026-03-10. Glofitamab has already achieved regulatory approval in multiple jurisdictions: the European Medicines Agency granted approval on 24 July 2025 under the brand name COLUMVI (EMA product number EMEA/H/C/005751), and the Australian Therapeutic Goods Administration approved the product on 1 March 2026, listing it under PBS codes 15227K, 15228L, 15249N, 15250P, 15266L, and 15269P. The regulatory approvals in Europe and Australia precede the completion of the Phase 2 trial in China, suggesting that efficacy and safety data from earlier-stage studies have supported market authorization. Peking University Third Hospital is sponsoring the development program without disclosed external partnership arrangements. The mechanism of action targets CD20, a well-established antigen on B-lymphoid cells, positioning glofitamab within the established anti-CD20 therapeutic class for hematologic malignancies.

Mantle cell lymphoma is an aggressive B-cell non-Hodgkin lymphoma with limited treatment options and poor prognosis, representing a significant unmet medical need despite existing therapies. The CD20-targeting approach is well-validated in lymphoid malignancies, but glofitamab's specific formulation and pharmacokinetic profile may offer clinical advantages in efficacy, tolerability, or dosing convenience compared to existing anti-CD20 agents. The rapid progression from clinical development to regulatory approval in Europe and Australia suggests strong clinical efficacy signals and favorable safety data, positioning glofitamab as a potentially important addition to the MCL treatment armamentarium. Market relevance is substantial given the orphan/rare disease status of MCL and the premium pricing typical of novel oncology therapeutics. Competitive positioning against existing anti-CD20 and other anti-lymphoma agents (proteasome inhibitors, kinase inhibitors, tubulin inhibitors) will depend on comparative efficacy, safety, and convenience metrics. The patient population for MCL is relatively small but represents a high-value segment in oncology, with significant commercial potential in developed markets. Glofitamab's approval in Australia and Europe establishes a commercial foothold and generates real-world evidence that may support future label expansions or approvals in additional jurisdictions, including the United States.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01); B-cell-targeting monoclonal antibody or antibody-like agent.

Mechanism of Action: B-lymphocyte antigen CD20 binding agent. CD20 is a transmembrane phosphoprotein expressed on B-lymphoid cells; binding to CD20 triggers B-cell destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis.

Modality: Small molecule (as classified in the development record).

Target: B-lymphocyte antigen CD20 (cluster of differentiation 20).

Route of Administration: Not yet disclosed.

Related Therapies: Other CD20-targeting agents in the anti-lymphoma space; proteasome inhibitors (e.g., KYPROLIS [carfilzomib]); tyrosine kinase inhibitors targeting ALK (e.g., ALUNBRIG [brigatinib]); tubulin inhibitors (e.g., CABAZITAXEL); and dual specificity mitogen-activated protein kinase kinase inhibitors (e.g., MEKTOVI [encorafenib]).

First Approval: European Union (24 July 2025); Australia (1 March 2026).

Patent Status: Not yet disclosed.

European Union: COLUMVI (glofitamab) received marketing authorization from the European Medicines Agency on 24 July 2025 under EMA product number EMEA/H/C/005751. Marketing authorization holder: Roche Registration GmbH.

Australia: Glofitamab approved by the Therapeutic Goods Administration effective 1 March 2026. Listed on the Australian Register of Therapeutic Goods (ARTG) under PBS codes 15227K, 15228L, 15249N, 15250P, 15266L, and 15269P. Sponsor: Roche Products Pty Ltd.

China: Glofitamab is in clinical trial phase in China. Active trial NCT07460362 is registered on ClinicalTrials.gov, indicating Phase 2 development status as of 10 March 2026. No regulatory approval in China has been disclosed.

United States (FDA): Regulatory status in the United States is not yet disclosed.

Japan (PMDA): Regulatory status in Japan is not yet disclosed.

Strategic Implications: Peking University Third Hospital's sponsorship of glofitamab development, combined with Roche's regulatory and commercial involvement (as evidenced by Roche's role as MAH in Europe and sponsor in Australia), suggests a collaboration or licensing arrangement not formally disclosed in the available facts. The approval timeline—EMA authorization in July 2025 followed by Australian approval in March 2026—indicates a deliberate regulatory strategy prioritizing European and Australian markets before or concurrent with completion of the Phase 2 China trial. This sequencing may reflect earlier completion of pivotal trials outside China or a decision to pursue accelerated pathways in certain jurisdictions.

Competitive Implications: Glofitamab's entry into the MCL market with CD20-targeting mechanism positions it as a direct competitor to established anti-CD20 agents and an alternative to proteasome inhibitors, kinase inhibitors, and other mechanisms. The competitive set provided does not include direct CD20-targeting comparators, suggesting either that the facts do not enumerate all relevant competitors or that glofitamab occupies a distinct niche. Commercial success will depend on clinical trial readouts demonstrating superior efficacy, improved tolerability, or enhanced convenience versus existing standards of care.

Future Catalysts: Completion and disclosure of Phase 2 trial results (NCT07460362) represents the primary near-term catalyst. Potential regulatory submissions to the FDA and PMDA could follow positive Phase 2 data. Label expansion trials in other lymphoid malignancies or combination therapy studies may extend the commercial opportunity. Real-world evidence from European and Australian markets will inform future development strategy and competitive positioning.

Expected Milestones: No specific next milestone date or label has been disclosed. Anticipated catalysts include Phase 2 trial completion and results publication, potential Phase 3 initiation or regulatory filing, and FDA/PMDA submissions.